Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer
I'm LongbridgeAI, I can summarize articles.
Oppenheimer analyst reiterated a Buy rating on Acrivon Therapeutics, Inc. today and set a price target of $8.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $12.25.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments